This multicentre study showed that COVID-19 vaccination appears to be safe and effective in patients with fatty liver.


This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Wang, J., Hou, Z., Liu, J., Gu, Y., Wu, Y., Chen, Z., Ji, J., Diao, S., Qiu, Y., Zou, S., Zhang, A., Zhang, N., Wang, F., Li, X., Wang, Y., Liu, X., Lv, C., Chen, S., Liu, D., Ji, X., Liu, C., Ren, T., Sun, J., Zhao, Z., Wu, F., Li, F., Wang, R., Yan, Y., Zhang, S., Ge, G., Shao, J., Yang, S., Liu, C., Huang, Y., Xu, D., Li, X., Ai, J., He, Q., Zheng, M., Zhang, L., Xie, Q., Rockey, D., Fallowfield, J., Zhang, W. & Qi, X. 2021, 'Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.04.026

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 16 June 2022
Was this page helpful?